With the publication of these clinical studies, the NCCN guidelines recommended pembrolizumab plus chemotherapy, with or without bevacizumab as the first-line therapy for patients with PD-L1-positive advanced cervical cancer, and nivolumab as the second-line therapy for PD-L1-positive cervical cancer. Here, CD274 is linked to cervical cancer.